These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35733400)

  • 1. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
    van Riel LAMJG; Jager A; Meijer D; Postema AW; Smit RS; Vis AN; de Reijke TM; Beerlage HP; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221088536. PubMed ID: 35356754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy.
    Wei G; Kelly BD; Timm B; Perera M; Lundon DJ; Jack G; Bolton DM
    BJUI Compass; 2021 May; 2(3):194-201. PubMed ID: 35475133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
    Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
    Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
    Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L
    Front Oncol; 2020; 10():603384. PubMed ID: 33489907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
    Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
    JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
    Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
    BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
    Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
    Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
    Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
    BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Patel HD; Koehne EL; Shea SM; Bhanji Y; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Gupta GN
    Cancer; 2022 Jan; 128(1):75-84. PubMed ID: 34427930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
    Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
    Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
    Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
    Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M
    World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
    Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
    Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
    Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective analysis of clinically significant prostate cancer detection with [
    Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.